Market Overview

UPDATE: Credit Suisse Reiterates Neutral Rating, Raises PT on Medtronic

Share:
Related MDT
What Specific Role Will Apple Play In IBM's Watson Health Cloud Alliance?
The Big Health Data Orgy Happening In The Cloud
FDA clears Medtronic balloon dilation catheter (Seeking Alpha)

In a report published Wednesday, Credit Suisse Group reiterated its Neutral rating on Medtronic (NYSE: MDT), and slightly raised its price target from $46.00 to $47.00.

Credit Suisse noted, “We see the last 2 Qs as evidence of MDT's ability to drive an improving top-line through emerging markets execution, recovery in key developed markets & M&A. Given MDT's improving top-line and conservative guidance we believe the company is the best positioned among the large-cap cardio names for near-term share price upside (though we highlight added BMP fallout as a near-term risk). We're raising our price target to $47 from $46 on a lower assumed WACC.”

Medtronic closed on Tuesday at $42.66.

Latest Ratings for MDT

DateFirmActionFromTo
Mar 2015BMO CapitalMaintainsOutperform
Feb 2015JefferiesMaintainsBuy
Dec 2014Bank of AmericaMaintainsBuy

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: Credit Suisse GroupAnalyst Color Price Target Analyst Ratings

 

Related Articles (MDT)

Around the Web, We're Loving...

Get Benzinga's Newsletters